| Literature DB >> 31704805 |
Daniel Aggio1, Efstathios Papachristou2, Olia Papacosta3, Lucy T Lennon3, Sarah Ash3, Peter Whincup4, S Goya Wannamethee3, Barbara J Jefferis3.
Abstract
INTRODUCTION: It is well established that physical activity (PA) protects against mortality and morbidity, but how long-term patterns of PA are associated with mortality and cardiovascular disease (CVD) remains unclear.Entities:
Keywords: CHD/coronorary heart; ageing; cardiovascular disease; life course epidemiology; physical activity
Mesh:
Year: 2019 PMID: 31704805 PMCID: PMC6993021 DOI: 10.1136/jech-2019-212706
Source DB: PubMed Journal: J Epidemiol Community Health ISSN: 0143-005X Impact factor: 3.710
Figure 1Group-based trajectory modelling-derived physical activity trajectories and 95% CI from midlife to old age (n=3231).
Subject characteristics at 20 year follow-up according to GBTM physical activity trajectories (n=3231)
| Characteristic | Low decreasing (n=733) | Light stable (n=1649) | Moderate increasing (n=849) | All (n=3231) |
| Age, years (mean ± SD) | 69.4 (5.6) | 68.5 (5.6) | 67.8 (5.1) | 68.5 (5.5) |
| Manual occupation (%, n)* | 59.8 (438) | 55.6 (916) | 38.5 (327) | 52.0 (1681) |
| Alcohol consumption, ≥light† (%, n) | 54.6 (400) | 62.4 (1029) | 73.5 (591) | 63.5 (1178) |
| Current smoker (%, n) | 19.5 (143) | 10.6 (174) | 7.4 (63) | 11.8 (380) |
| Married (%, n) | 80.5 (590) | 85.0 (1402) | 86.9 (738) | 84.5 (2730) |
| Resident in southern England (%, n)* | 26.2 (192) | 36.2 (597) | 38.2 (324) | 34.5 (1113) |
| Waist circumference, cm (mean±SD) | 100.1 (11.2) | 96.4 (10.0) | 95.4 (9.5) | 97.0 (10.3) |
| LDL, mmol/L (mean±SD) | 3.8 (1.0) | 4.0 (1.0) | 3.9 (0.9) | 3.9 (1.0) |
| HDL, mmol/L (mean±SD) | 1.3 (0.3) | 1.3 (0.3) | 1.4 (0.3) | 1.3 (0.3) |
| Insulin, μ/mL (median, IQR) | 9.6 (8.1) | 8.1 (5.9) | 7.5 (5.4) | 8.2 (6.4) |
| SBP, mm Hg (mean±SD) | 148.6 (23.9) | 149.0 (23.8) | 148.0 (24.4) | 148.6 (24.0) |
| FEV1, L‡ (mean±SD) | 235.2 (69.5) | 259.6 (62.5) | 276.1 (61.7) | 258.4 (65.5) |
| IL-6, pg/mL (median, IQR) | 2.8 (2.4) | 2.2 (1.8) | 2.0 (1.5) | 2.2 (1.9) |
| vWf, IU/dL (mean±SD) | 148.7 (48.4) | 137.1 (45.0) | 133.6 (43.0) | 138.8 (45.6) |
| Hs-TnT, pg/mL (median, IQR) | 12.7 (8.1) | 11.4 (7.0) | 11.5 (6.3) | 11.7 (7.0) |
| NT-proBNP, pg/mL (median, IQR) | 112.0 (206.0) | 88.0 (136.0) | 78.0 (111.0) | 89.0 (144) |
| Previous MI (%, n) | 9.1 (67) | 7.3 (120) | 6.0 (51) | 7.4 (238) |
| Previous stroke (%, n) | 3.3 (24) | 2.4 (39) | 2.2 (19) | 2.5 (82) |
| Previous diabetes (%, n) | 14.5 (106) | 7.4 (122) | 7.0 (59) | 8.9 (287) |
*Reported at baseline.
†light classified as ≥1 unit per week.
‡Standardised for height by multiplying FEV1 by the square of the mean population height (metres) divided by each participant’s height.
FEV1, forced expiratory volume in 1 s;GBTM, group-based trajectory modelling; HDL, high-density lipoprotein; Hs-TnT, high-sensitivity cardiac troponin T; IL-6, interleukin 6; LDL, low-density lipoprotein; MI, myocardial infarction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SBP, systolic blood pressure; vWf, von Willebrand factor.
Association between physical activity trajectories and subsequent risk of CVD events and all-cause and CVD mortality (n=3231)
| Outcome | Trajectory group | N | No. of events | Person-years | Rate per 1000 person-years | Model 1 | Model 2 | Model 3 | Model 4 |
| HR (95% CI) | |||||||||
| Deaths (all cause) | Low decreasing | 733 | 494 | 8402.2 | 58.8 | Referent | Referent | Referent | Referent |
| Light stable | 1649 | 869 | 22 216.5 | 39.1 |
|
|
|
| |
| Moderate increasing | 849 | 372 | 12 034.9 | 30.9 |
|
|
|
| |
| p trend | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| CVD mortality* | Low decreasing | 733 | 198 | 8402.2 | 23.6 | Referent | Referent | Referent | Referent |
| Light stable | 1649 | 297 | 22 216.5 | 13.4 |
|
|
|
| |
| Moderate increasing | 849 | 115 | 12 034.9 | 9.6 |
|
|
|
| |
| p trend | <0.001 | <0.001 | <0.001 | <0.001 | |||||
| All CVD events (fatal +non-fatal)† | Low decreasing | 733 | 252 | 7901.3 | 31.9 | Referent | Referent | Referent | Referent |
| Light stable | 1649 | 470 | 20 692.5 | 22.7 |
|
| 0.85 (0.72 to 1.00) | 0.89 (0.75 to 1.04) | |
| Moderate increasing | 849 | 198 | 11 338.1 | 17.5 |
|
|
|
| |
| p trend | <0.001 | 0.002 | 0.009 | 0.015 | |||||
| CHD events (fatal+non-fatal)‡ | Low decreasing | 733 | 146 | 8190.7 | 17.8 | Referent | Referent | Referent | Referent |
| Light stable | 1649 | 245 | 21 531.7 | 11.4 |
|
|
|
| |
| Moderate increasing | 849 | 98 | 11 672.4 | 8.4 |
|
|
|
| |
| p trend | 0.001 | 0.004 | 0.009 | 0.012 | |||||
| Stroke events (fatal+non-fatal)§ | Low decreasing | 733 | 76 | 8098.6 | 9.4 | Referent | Referent | Referent | Referent |
| Light stable | 1649 | 186 | 21 308.6 | 8.7 | 0.99 (0.75 to 1.31) | 1.04 (0.79 to 1.38) | 1.08 (0.82 to 1.43) | 1.10 (0.83 to 1.46) | |
| Moderate increasing | 849 | 84 | 11 687.7 | 7.2 | 0.87 (0.63 to 1.20) | 0.92 (0.66 to 1.28) | 0.96 (0.69 to 1.34) | 0.98 (0.70 to 1.37) | |
| p trend | 0.368 | 0.573 | 0.773 | 0.851 | |||||
Model 1, adjusted for age, occupational class, marital status, alcohol consumption, smoking status, region, previous diagnosis of MI, stroke or diabetes.
Model 2, Model 1+LDL, HDL, systolic blood pressure, insulin, waist circumference and FEV1.
Model 3, Model 2+IL-6 and vWf.
Model 4, Model 3+Hs TnT and NT-proBNP.
Boldface indicates statistical significance (p<0.05).
*Fatal CVD was defined as ICD-9 codes 390–459.
†All CVD events included all fatal CVD (ICD-9 codes 390–459) and non-fatal MI and stroke as described above.
‡Fatal myocardial infarction (MI) was defined as ICD-9 codes 410–414. Non-fatal MI was defined as heart attack or coronary thrombosis, in accordance with the WHO diagnostic criteria.
§Fatal stroke was defined as ICD-9 codes 430–438. Non-fatal stroke events included those that caused a neurological deficit for >24 hours.
CHD, coronary heart disease; CVD, stroke/MI; MI, myocardial infarction.